Onco Wiki / Indication

Ovarian carcinoma (high-grade serous predominant) · line 2 · Rucaparib maintenance (recurrent platinum-sensitive ovarian, ARIEL3)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy2
Trackaggressive
Linked regimenREG-RUCAPARIB-MAINT-OVARIAN
IDIND-OVARIAN-MAINT-PARPI-RUCAPARIB
TypeIndication
Statusreviewed 2026-04-27 | pending_clinical_signoff
DiseasesDIS-OVARIAN
SourcesSRC-ARIEL3-COLEMAN-2017 SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025

Notes

ESCAT IA. UA-access: rucaparib not registered as of 2026-04 — олапариб (BRCA-mut) і нірапариб (HRD+) є реалістичні UA-доступні альтернативи.

Used By

Algorithms

Indication